Medicare Part B pays for one prostate-specific antigen (PSA) blood test every 12 months for all male beneficiaries aged 50 and older. The PSA blood test, when billed as a preventive screening, comes at no out-of-pocket cost: no copayment, no coinsurance, and no Part B deductible. That once-a-year frequency and zero-cost structure sounds simple, but several wrinkles around related exams, what happens if you test more often, and whether the test is even a good idea at your age make the real picture more layered than it first appears.
What Medicare Actually Covers for Prostate Screening
Medicare’s prostate cancer screening benefit has two distinct components, and they are not treated equally when it comes to cost sharing. The PSA blood test itself is fully covered as a preventive service, meaning you owe nothing as long as 12 months have passed since your last covered screening. The second component, the digital rectal examination (DRE), is a separate service code, and it does carry a copayment or coinsurance along with the Part B deductible.1Noridian Healthcare Solutions. Prostate Cancer Screening – JE Part B – Section: Payment Many men assume the entire screening visit is free. The blood draw portion is, but if your doctor performs a DRE during the same visit, expect the standard cost-sharing rules to apply to that part.
The 12-month clock resets from the date of your last covered PSA screening, not from a calendar year. If you had a screening PSA drawn in March 2024, Medicare will cover the next one any time on or after March 2025. You do not have to wait until January of the following year.
What Happens If You Get Tested More Often
Sometimes a doctor wants to check your PSA sooner than 12 months. Maybe a previous result was borderline, or you have symptoms that raise concern. Medicare still has rules here, and understanding them can save you an unexpected bill.
All Medicare screening lab tests operate on a set frequency, and any test ordered more frequently than that schedule requires the provider to give you an Advance Beneficiary Notice of Noncoverage (ABN) before the blood is drawn.2Noridian Healthcare Solutions. Advance Beneficiary Notice of Noncoverage (ABN) – JE Part B – Section: Laboratory The ABN is a written notice telling you that Medicare is unlikely to pay for the service and that you may be financially responsible. You then choose whether to go ahead anyway and accept the cost or skip it. If a provider fails to give you a valid ABN before performing the test, they cannot bill you for it even if Medicare denies the claim.
There is an important distinction between a “screening” PSA and a “diagnostic” PSA. When a doctor orders a PSA because you have urinary symptoms, a suspicious DRE finding, or a known history of prostate issues, that test is coded as diagnostic rather than screening. Diagnostic PSA tests are processed under regular Part B medical coverage, not the preventive screening benefit, which means the Part B deductible and 20% coinsurance apply. However, diagnostic tests are not locked into the once-every-12-months rule. Your doctor can order them as often as medically necessary without an ABN, as long as there is a clinical reason documented. So if your concern is that you need monitoring more than once a year because of an abnormal result, the answer is usually that Medicare will cover repeat testing under a diagnostic code, though you will owe the usual cost sharing.
The Conversation That Should Happen Before You Get Tested
Medical guidelines from both the U.S. Preventive Services Task Force and the American Urological Association emphasize that PSA screening should involve shared decision-making. The idea is straightforward: before ordering the test, your doctor should walk you through both the potential benefits (catching cancer early) and the potential harms (false positives, unnecessary biopsies, overtreatment of slow-growing cancers that might never cause problems). You should then decide together whether testing makes sense for you.
In practice, that conversation happens inconsistently. A review of the evidence on shared decision-making before PSA screening found that the reported prevalence of it actually occurring ranged wildly, from as low as 11% to as high as 98%, depending on who was asked and how the study measured it. Physicians tended to report having these conversations far more often than patients recalled. Discussion of the advantages of PSA testing happened in roughly 20% to 89% of encounters across studies, while discussion of the disadvantages happened in just 6% to 79%. When researchers looked at whether both sides were covered in a single conversation, rates ranged from about 12% in patient-reported data to 89% in physician-reported data.3PubMed Central. Shared decision-making before prostate cancer screening decisions
This gap matters because Medicare coverage does not require your doctor to prove that shared decision-making occurred. The test gets covered regardless. But the guidelines exist because PSA screening is one of those areas where a normal result gives peace of mind and an abnormal result can set off a chain of follow-up procedures, some of which carry real risks. Asking your doctor to explain both sides before you roll up your sleeve is worth the extra few minutes.
How Screening Recommendations Have Changed and What That Means for You
Medicare’s once-a-year coverage has remained steady, but the professional recommendations around whether men should actually use that benefit have swung back and forth over the past two decades, and those shifts have measurably changed how many Medicare beneficiaries get screened.
In 2008, the U.S. Preventive Services Task Force recommended against routine PSA screening for men aged 75 and older, citing concerns about overdiagnosis and overtreatment. In 2012, the Task Force extended that recommendation to all age groups, giving PSA screening a “D” rating (meaning they recommended against it). Those recommendations clearly influenced behavior. An analysis of Medicare claims found that PSA screening utilization among men 75 and older declined after the 2008 recommendation, with the odds of receiving a PSA test dropping by about 17%. After the broader 2012 recommendation, the odds of screening dropped by roughly 29% among men 65 and older.4Journal of Clinical Oncology. Impact of USPSTF recommendations on utilization of PSA screening in Medicare beneficiaries
Then, in 2018, the Task Force partially reversed course. For men aged 55 to 69, the recommendation was upgraded to a “C” rating, meaning the decision should be individual and based on shared decision-making. For men 70 and older, the recommendation against screening remained. Medicare, however, did not change its coverage policy in response to any of these shifts. The benefit still covers one PSA test per year for all men 50 and older, regardless of what the Task Force says. This creates an odd disconnect: Medicare will pay for a screening that the country’s leading preventive-medicine panel says most men over 70 should probably skip.
Why Age Matters More Than the Coverage Rules Suggest
The fact that Medicare covers the test does not automatically mean the test is a good idea, and the clearest illustration of this comes from the data on screening in older men. A large study of Medicare Advantage enrollees aged 70 and older found that nearly 39% of them received a PSA test that researchers classified as low-value screening, meaning a test ordered for men in age groups where guidelines generally recommend against it.5PubMed Central. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending That is a substantial share of older men getting a covered test that expert panels say is more likely to cause harm than benefit at their age.
The concern is not just the blood draw itself, which is cheap and painless. It is what happens afterward. Among the men over 70 who received a low-value PSA screening in that study, nearly 63% went on to receive at least one follow-up service, such as another PSA test, a biopsy, imaging, or even treatment like radiation or surgery. About 7% ended up with high-cost follow-up services. The study calculated that for every dollar spent on the initial low-value PSA test, an additional six dollars was spent on the downstream care it triggered.5PubMed Central. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending That cascade is exactly what guidelines are trying to prevent: a screening test that is free to the patient but launches a sequence of interventions, each carrying cost, inconvenience, and potential side effects, in a population where slow-growing prostate cancers are unlikely to be the thing that shortens a man’s life.
None of this means that PSA testing is always wrong for men over 70. A man in excellent health with a long life expectancy and a family history of aggressive prostate cancer might reasonably choose to keep screening. The point is that “Medicare covers it” and “it’s the right choice for me” are two different questions, and the second one deserves a real conversation with your doctor.
Does PSA Screening Actually Save Lives
This is the question underneath every coverage and frequency discussion, and the evidence is genuinely mixed, which is why the guidelines have bounced around. A large U.S. county-level analysis found a clear statistical relationship between PSA testing rates and both prostate cancer treatment rates and prostate cancer mortality. For every 100,000 men who received a PSA test, about 4,894 additional men underwent a prostate biopsy, roughly 1,597 additional men received prostate cancer treatment, and 61 fewer men died from prostate cancer over the following nine years.6PubMed Central. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States Those numbers reveal the tension at the heart of PSA screening. You can see the mortality benefit: 61 fewer prostate cancer deaths per 100,000 screened men is real. But you can also see the cost: nearly 5,000 biopsies and about 1,600 courses of treatment to get there, many of which were likely for cancers that would never have become lethal.
The same study found no relationship between PSA testing rates and death from other causes, which suggests the mortality drop was genuinely from catching prostate cancer rather than from screened men simply being healthier overall. But the ratio of men treated to men whose lives were saved is steep. For roughly every 26 men treated for prostate cancer in this analysis, one prostate cancer death was prevented. The other 25 received treatment that came with risks of its own, including urinary incontinence and sexual dysfunction, for cancers that might never have threatened their lives.
This is why screening guidelines have migrated toward individualized decision-making rather than blanket recommendations for or against. The test can save lives, but it can also lead to real harm through overdiagnosis and overtreatment. Medicare’s coverage policy does not weigh in on that tradeoff. It simply makes the test available once a year and leaves the decision to you and your doctor.
Medicare Advantage Plans and PSA Testing
If you have a Medicare Advantage plan rather than Original Medicare, the basic PSA screening benefit applies the same way: one covered test every 12 months, no cost sharing for the screening blood draw. Medicare Advantage plans are required to cover at least everything Original Medicare covers, so the preventive screening benefit carries over. However, the specifics of how follow-up care is handled, which providers are in-network, and what your cost sharing looks like for a diagnostic PSA or a biopsy can vary significantly from plan to plan.
The research on low-value PSA screening cited earlier was actually conducted among Medicare Advantage enrollees specifically, which means the pattern of frequent screening in older men and the resulting care cascades are not just a theoretical concern in that population.5PubMed Central. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending If anything, Medicare Advantage plans have stronger managed-care tools to reduce low-value services, and yet nearly four in ten men over 70 in the study still received a PSA screen. The coverage structure makes stopping easy: just decline the test. But the cultural momentum behind “getting your PSA checked” can be hard to push back against, especially when the blood draw is free and takes 30 seconds.
Practical Tips for Managing Your PSA Screening Under Medicare
A few things are worth keeping in mind when you schedule your next screening or talk with your doctor about whether to screen at all.
- Track your own dates: Medicare’s 12-month window starts from the date of your last covered screening, not from a calendar year. If your doctor’s office does not track this precisely, you could accidentally be billed for a test that is a few weeks too early. Keep a note of the date.
- Know your billing codes: A screening PSA (typically billed under code G0103) has no cost sharing. A diagnostic PSA (billed under a standard lab code with a medical diagnosis attached) carries the usual 20% coinsurance after your deductible. If your doctor is ordering the test because of symptoms or an abnormal prior result, it will likely be diagnostic, and you should expect some out-of-pocket cost.
- Ask about the ABN: If your provider hands you an ABN before a PSA test, that is a signal Medicare may not cover it, usually because you are testing more frequently than once a year under the screening benefit. Read it before signing. You have the right to decline the test.
- Request the full conversation: If your doctor orders a PSA without discussing the pros and cons, ask for that discussion. The test is most beneficial when it is part of an informed, individualized decision rather than a routine checkbox.
When a Rising PSA Triggers a Different Coverage Path
Once you have had an elevated PSA result or a prostate cancer diagnosis, you move out of screening territory entirely and into diagnostic and treatment coverage, which operates under different rules. Repeat PSA tests to monitor a known condition, biopsies, MRIs, and treatments like surgery or radiation are all covered under standard Part B medical benefits with the usual deductible and coinsurance. There is no annual frequency limit for diagnostic and monitoring PSA tests as long as your doctor documents a medical reason for each one.
This transition matters because men sometimes conflate “screening” with “monitoring.” If you have already been diagnosed with prostate cancer or are on active surveillance for a low-grade cancer, your PSA tests are not screening tests anymore. They are part of your medical care, and Medicare covers them accordingly. The once-a-year limit and the zero-cost-sharing rules apply only to the initial screening context, when you are asymptomatic and looking for problems that have not been found yet.
For men on active surveillance, PSA levels are typically checked every few months along with periodic biopsies or imaging. That monitoring schedule is between you and your urologist, and Medicare does not impose the 12-month interval on it. Your cost sharing will be whatever your plan’s standard Part B terms are, but the frequency is driven by clinical need, not a preventive-services calendar.